The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | N | Nervous system | |
| 2 | N03 | Antiepileptics | |
| 3 | N03A | Antiepileptics | |
| 4 | N03AC | Oxazolidine derivatives | |
| 5 | N03AC02 | Trimethadione |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 1.5 g |
| Active Ingredient | Description | |
|---|---|---|
| Trimethadione |
Trimethadione is an antiepileptic agent. Trimethadione has been shown to prevent pentylenetetrazol-induced and thujone-induced seizures in experimental animals; the drug has a less marked effect on seizures induced by picrotoxin, procaine, cocaine, or strychnine. Unlike the hydantoins and antiepileptic barbiturates, trimethadione does not modify the maximal seizure pattern in patients undergoing electroconvulsive therapy. |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
